Treatments to be considered in July 2015

The Pharmaceutical Benefits Advisory Committee is meeting in July 2015 and will be considering the following medicines for the treatment of hepatitis C.

New medicines being considered:

  • Paritaprevir with ritonavir, ombitasvir and dasabuvir (Viekira Pak®) - for the treatment of hepatitis C, genotype 1
  • Paritaprevir with ritonavir, ombitasvir, dasabuvir and ribavirin (Viekira Pak-RBV®) for the treatment of hepatitis C, genotype 1
    Please note the above two, multi-agent medicines are listed on the PBAC agenda as a single entry. 

Existing medicines being considered for additional uses:

  • Simeprevir (Olysio®) - submission is for use in an interferon-free combination with sofosbuvir for the treatment of hepatitis C, genotype 1
  • Ribavirin (Ibavyr®) - as per submission to March meeting with revisions. 

Treatments considered in March 2015 

  • Asunaprevir (Sunvepra®) - for the treatment of chronic genotype 1b hepatitis C (has not been recommended  at this time)
  • Daclatasivir (Daklinza®) - for the treatment of chronic hepatitis C (has been recommended for PBS listing, pending government approval)
  • Ledipasvir + sofosbuvir (Harvoni®) - for the treatment of genotype 1 chronic hepatitis C virus infection in adult patients. (has been recommended for PBS listing, pending government approval)
  • Sofosbuvir (Sovaldi®) – for the treatment of chronic hepatitis C infection. (has been recommended for PBS listing, pending government approval)
  • Ribavirin (Ibavyr®) – for the treatment of chronic hepatitis C (genotype 2 or 3) in combination with sofosbuvir in adult patients who have compensated liver disease. (no change to existing listing recommended at this time)

Page updated: 11 May 2015